Investment Thesis
Upstream Bio is a development-stage pharmaceutical company with a fortress balance sheet ($96.7M cash, minimal debt) providing downside protection, but severe operating losses ($43.6M) against minimal revenue ($1.0M) create existential burn risk. With annual negative cash flow of $48M, the company has approximately 2 years of runway to achieve clinical or commercial milestones before requiring capital raises.
Strengths
- Strong balance sheet with $96.7M cash reserves and only $14.1M total liabilities
- Zero long-term debt eliminates financial distress risk in near term
- Exceptional liquidity position (23.14x current ratio) supports extended operations
- Revenue growth of 20.4% YoY indicates emerging commercial traction despite early stage
Risks
- Operating losses of $43.6M against $1.0M revenue indicates severe unprofitability and pre-revenue stage
- Negative free cash flow of $48M annually with only $96.7M runway (~2 years at current burn)
- Pharmaceutical development carries high clinical, regulatory, and execution risk with uncertain outcomes
- Heavy R&D burn model typical of biotech requires successful commercialization or significant capital raises
Key Metrics to Watch
- Operating cash flow trajectory and path to cash flow breakeven
- Clinical trial advancement, regulatory approvals, and drug development pipeline milestones
- Revenue growth rate from product commercialization or licensing revenues
Financial Metrics
Revenue
1.0M
Net Income
-40.6M
EPS (Diluted)
$-0.75
Free Cash Flow
-48.0M
Total Assets
318.1M
Cash
96.7M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-4,218.1%
Net Margin
-3,925.6%
ROE
-13.4%
ROA
-12.8%
FCF Margin
-4,643.8%
Balance Sheet & Liquidity
Current Ratio
23.14x
Quick Ratio
23.14x
Debt/Equity
0.00x
Debt/Assets
4.4%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-14T06:59:19.649873 |
Data as of: 2026-03-31 |
Powered by Claude AI